Key Highlights
● Novavax plunged to about $11.20 and PacBio sank to $1.74 in a broad biotech retreat.
● Higher long-term yields cut the present value of distant profits for clinical-stage companies.
● Omeros fell after the EMA committee kept its negative opinion on narsoplimab.
● City Therapeutics priced its IPO at $18 a share, raising about $200 million.
A broad biotech retreat
Smaller biotech and life-sciences stocks were among Friday's hardest-hit groups. Novavax (NASDAQ:NVAX) plunged to about $11.20, and PacBio (NASDAQ:PACB) sank to $1.74. Ocular Therapeutix (NASDAQ:OCUL), QuidelOrtho (NASDAQ:QDEL), Azenta (NASDAQ:AZTA), Myriad Genetics (NASDAQ:MYGN) and Repligen (NASDAQ:RGEN) also fell. There was no company-specific news for most of them, pointing to a rate-driven selloff in long-duration and clinical-stage health care names.
Moderna (NASDAQ:MRNA) sank as investors trimmed positions ahead of Phase 3 data on intismeran, developed with Merck (NYSE:MRK), due later this month. The stock has soared this year. Goldman Sachs raised its price target to $137 from $120 while keeping a Neutral rating, according to reports.
The selling came as the Russell 2000 fell 45.90 points to about 2,721, the S&P 500 dropped 84.62 points to 7,659.44 and the Nasdaq Composite slid 572.99 points to 26,140.03.
Why yields matter
Most clinical-stage biotech companies do not yet earn profits. Their valuations rest on revenue that may arrive years from now, if their drugs succeed. When long-term interest rates rise, the present value of those distant cash flows falls, and higher rates also make it costlier for cash-burning companies to raise money.
Long-term yields remain elevated. The 10-year Treasury yield ended the week near 5.1 after topping 5.3 earlier in October, its highest since 2002. The 30-year yield sat around 5.42, below its Oct 7 peak. A head investment strategist at the Franklin Templeton Institute said that "pressure across the long end of the curve acts as a valuation headwind for risk assets."
The Federal Reserve raised rates a quarter point in September, its first hike in three years, and inflation data this week ran hot. Fed Chair Kevin Warsh offered no signal on the next move, saying: "I don't prejudge meetings." His Bangkok remarks emphasized price stability.
Company-specific news
A few names had their own catalysts. Omeros (NASDAQ:OMER) fell after the European Medicines Agency's CHMP kept its negative opinion on narsoplimab following a re-examination. Chief executive Gregory A. Demopulos said: "We are deeply disappointed in the re-examination process and outcome." Omeros said it will end its EU compassionate-use program and pursue named-patient access instead.
MDxHealth (NASDAQ:MDXH) reported preliminary third-quarter revenue of about $22.7 million, below the $24.55 million estimate, and suspended its full-year guidance. On the positive side, Anavex Life Sciences (NASDAQ:AVXL) said the FDA cleared its application to study blarcamesine in Fragile X syndrome, setting up a Phase 2a trial.
Big pharma held up
The weakness was concentrated in smaller companies. Large health care stocks benefited from Friday's rotation into defensive sectors, and the Health Care Select Sector SPDR fund hit records. McKesson (NYSE:MCK) set an intraday record. Eli Lilly (NYSE:LLY) received a positive CHMP opinion this week on its oral drug Foundayo.
City Therapeutics (NASDAQ:CTY) priced its initial public offering at $18 a share, raising about $200 million, according to market reports, in a test of appetite for new biotech issues.
Intismeran Data Anchors Biotech Calendar
The Federal Reserve's decision on Oct 28 and the path of long-term Treasury yields will remain central for rate-sensitive biotech. Health care earnings next week include Intuitive Surgical (NASDAQ:ISRG) on Tuesday and Thermo Fisher (NYSE:TMO), Abbott (NYSE:ABT) and Danaher (NYSE:DHR) on Wednesday. Moderna's Phase 3 intismeran data later this month is a key event for the sector.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...